Skip to content

Search for Genetic Factors in Parkinson's Disease - II

Search for Genetic Factors in Parkinson's Disease - II - GPS2 (The ErasmusMC Genetics of Parkinson Study - II)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON51549
Enrollment
700
Registered
2023-02-20
Start date
2023-02-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinsonism Parkinson's Disease

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
16 Years to 99 Years

Inclusion criteria

Inclusion criteria: - The probands (index cases) must have a diagnosis of idiopathic Parkinson's disease according to the established clinical criteria (familial or sporadic disease). - The relatives of the probands are first-, second-, or third-degrees relatives of the probands; they might or might not have Parkinson's disease. - Due to possible shared etio-pathogenetic pathways, relatives of PD probands - The unrelated controls, as well as their first degree relatives, must be free from clinical signs of Parkinson's disease and dementia. -All subjects (probands, relatives, controls) must be 16 years of age at recruitment. -All subjects (probands, relatives, controls) might be male or female. -All subjects (probands, relatives, controls) must have signed the informed consent (before entry into study). In case of a legally incapacitated subject, for instance due to cognitive impairment, the legal representative will be approached to obtain informed consent.

Exclusion criteria

Exclusion criteria: - Subjects who are unable to speak and be interviewed in Dutch or English (to ensure validity of the interviews). - Patients with secondary forms of parkinsonism (such as drug-induced, toxic, vascular, tumor)

Design outcomes

Primary

MeasureTime frame
- Genetics variants causing or predisposing to Parkinson's disease. - Characterisation of the clinical phenotype associated to specific genetic variants. - Investigation of molecular mechanisms of PD in patients with specific genetic variants.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)